Medeon Biodesign, Inc. (TPEX:6499)

Market Cap	8.99B
Revenue (ttm)	347.55M
Net Income (ttm)	-783.68M
Shares Out	92.14M
EPS (ttm)	-8.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,973,495
Average Volume	2,359,907
Open	90.00
Previous Close	89.10
Day's Range	90.00 - 97.60
52-Week Range	34.75 - 97.60
Beta	0.43
RSI	93.84
Earnings Date	May 8, 2025

About Medeon Biodesign

Medeon Biodesign, Inc. researches, develops, manufactures, and sells medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site hernia...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2012
• Employees: 39
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6499

Financial Performance

In 2024, Medeon Biodesign's revenue was 292.81 million, an increase of 49.19% compared to the previous year's 196.26 million. Losses were -805.51 million, -33.13% less than in 2023.